 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT  Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the...

DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

DBV Technologies S.A. (NASDAQ:DBVT Free Report) Analysts at HC Wainwright dropped their Q3 2023 earnings estimates for DBV Technologies in a report released on Tuesday, August 1st. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.15) per share for the quarter, down from ...

DBV Technologies S.A. (NASDAQ:DBVT) to Post Q3 2023 Earnings of ($0.15) Per Share, HC Wainwright Forecasts

JMP Securities reissued their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT Free Report) in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $4.00 price target on the stock. DBVT has been the subject of several other research reports. HC ...

DBV Technologies (NASDAQ:DBVT) Given "Market Outperform" Rating at JMP Securities

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoGen (IMGN Research Report), DBV Technologies... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoGen (IMGN Research Report), DBV Technologies ...

Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN), DBV Technologies SA - American (DBVT) and CymaBay Therapeutics (CBAY)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on DBV Technologies SA American (DBVT Research Report... In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on DBV Technologies SA  American (DBVT &#8211...

DBV Technologies SA - American (DBVT) Receives a Buy from JMP Securities

DBV Technologies GAAP EPS of -$0.26, revenue of $2.3M

Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a ...

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

Shares of DBV Technologies S.A. (NASDAQ:DBVT  Get Free Report) have been assigned an average recommendation of Moderate Buy from the five research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and four...

DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT Get Free Report) have earned a consensus recommendation of Moderate Buy from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy ...

DBV Technologies S.A. (NASDAQ:DBVT) Receives $6.67 Average PT from Brokerages

Research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a sell rating on the stock. DBV Technologies Price Performance Shares of DBVT opened at $1.79 on Wednesday. The firm ...

DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Watchers	2,302
52-Wk Low	$1.08
52-Wk High	$2.37

Market Cap	$261.39M
Volume (M)	85,256.00
52-Wk High	$2.37
52-Wk Low	$1.08

DBVT DBV Technologies

About

Feed

News

Sentiment

Earnings

Fundamentals